News | News By Subject | News by Disease News By Date | Search News

Dementia News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Eli Lilly (LLY) Dropped After Primary Goal of Alzheimer's Study Was Changed     3/18/2016
TauRx Completes $135 Million Funding Round to Support Phase III Trials for Key Products     10/8/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Intra-Cellular Therapies, Inc.'s Dementia Drug Meets Phase 1/2 Goals     10/13/2014
Major Drugmakers Like AstraZeneca PLC (AZN), GlaxoSmithKline (GSK). And Johnson & Johnson (JNJ) Link Up With Academia In Huge $27 Million UK Dementia Project     6/20/2014
Eli Lilly and Company (LLY) Aims Alzheimer's Treatment at Early Stage Patients     7/12/2013
UK Study Warns Against Johnson & Johnson (JNJ) (JOBS), Eli Lilly and Company (LLY) (JOBS), AstraZeneca PLC (AZN) (JOBS) Anti-Psychotics for Dementia     11/23/2009
FDA Approves Novartis Corporation (NVS)'s Exelon(R) As the First Medication Indicated To Treat Parkinson's Disease Dementia     6/28/2006
FDA Advisory Committee Recommends Approval Of Novartis Pharmaceuticals Corporation (NVS)'s Exelon(R) (rivastigmine tartrate) In The Treatment Of Dementia Associated With Parkinson's Disease     5/18/2006
Myriad Genetics, Inc. (MYGN) Reports Results Of Phase 2 Trial Of Flurizan(TM) In Patients With Alzheimer's Disease; Drug Misses Targets In Trial     5/2/2005
Icagen, Inc. (ICGN) Receives Milestone Payment From Yamanouchi Pharmaceutical Co., Ltd.     3/15/2005
Myriad Genetics, Inc. (MYGN) Initiates Earlier-Than-Expected Phase 3 Clinical Trial Of Flurizan(TM) In Alzheimer's Disease     1/13/2005
Memory Pharmaceuticals (MEMY) CFO Keane Resigns     12/15/2004

News from Around the Web
Dementia Risk Declines, And Education May Be One Reason Why, Published In JAMA     11/22/2016
Online Game About Lost Sea Hero Helps Scientists Studying Dementia     11/17/2016
Can Exercise Make You Smarter? New York University Scientists Think It's Possible     10/21/2016
Cosmic Radiation May Leave Astronauts With Long-Term "Space Brain," University of California, Irvine Study     10/19/2016
University of Pennsylvania Study Links Prostate Cancer Treatment To Dementia     10/14/2016
Traveling To Mars Might Cause Long-Term Brain Damage     10/12/2016
If You Were At Higher Risk Of Developing Dementia, Would You Want To Know?     9/20/2016
Can Pomegranates Protect The Brain From Dementia? University of New South Wales Reveals     9/1/2016
Calcium Supplements Tied To Higher Dementia Risk, University of Gothenburg Study     8/18/2016
Acupuncture May Slow Down Pre-Dementia Memory Loss, Renmin Hospital Of Wuhan University Study     8/5/2016
How Your Sight And Smell Could Be The Key For Early Detection Of Alzheimer's, Studies Reported at AAIC 2016 Reveal     7/27/2016
Changes In Personality, Behavior Could Be An Early Sign Of Dementia, University of Calgary Study     7/25/2016
"Brain Training" Cut Dementia Risk In Healthy Adults, University of South Florida Study     7/25/2016
Cancer Drug Could Help Parkinson's, Dementia Patients, Georgetown University Study     7/14/2016
A Medical Mystery Of The Best Kind: Major Diseases Are In Decline     7/12/2016

Press Releases
Lannett (LCI) Announces Approval For Memantine Hydrochloride Tablets USP, 5 mg And 10 mg     11/14/2016
Eisai Inc. (ESALF.PK) Initiates Phase 2 Clinical Trial To Evaluate Lemborexant In The Treatment Of Irregular Sleep-Wake Rhythm Disorder (ISWRD) In Dementia Patients     10/31/2016
Axovant (AXON) Receives FDA Fast-Track Designation For Intepirdine As An Investigational Treatment For Dementia With Lewy Bodies     9/26/2016
Cerebain Biotech Presents Update On Its Medical Device Research And Development As It Continues Its Battle Against Alzheimer’s And Dementia     9/13/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016     8/16/2016
Quest Diagnostics (DGX) Launches New Digital Dementia Assessment Test To Aid Physicians' Assessment Of Individuals With Cognitive Dysfunction     8/4/2016
AVANIR (AVNR) Release: NUEDEXTA Effective For Pseudobulbar Affect (PBA) In Patients With Alzheimer's Disease And Other Dementias, Stroke And Traumatic Brain Injury     6/9/2016
Axovant (AXON) Announces 2015 Fiscal Year-End Financial Results And Corporate Updates     6/6/2016
Eisai Company (ESALY.PK) Release: Aricept Approved In The Philippines For New Indication As Treatment For Dementia With Lewy Bodies     4/14/2016
Anavex (AVXL) Release: U.S. FDA Grants Orphan Drug Designation To ANAVEX 3-71 For The Treatment Of Frontotemporal Dementia     4/8/2016
Alzheimer’s Research UK Release: Rise In Deaths In 2015 Due To Impact Of Dementia And Respiratory Disease     4/7/2016
Neurotrope Announces Publication Demonstrating Synaptic Regeneration With The PKC Epsilon Activator Bryostatin, In A Fragile X Disease Late Brain Development Model     3/8/2016
Arena (ARNA) Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update     3/1/2016
Portage Biotech's Biohaven Announces Expedited Development Path For BHV-0223 Following Successful Pre-IND Interaction With FDA     2/25/2016
ANI Pharma And Dexcel Pharma Announce FDA Approval Of Donepezil Hydrochloride 23mg Tablets     2/24/2016

//-->